Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;46(1):2308701.
doi: 10.1080/0886022X.2024.2308701. Epub 2024 Feb 12.

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients

Wenhui Wu  1 , Nan Hu  2 , Xiurong Li  1 , Jia Di  1 , Hua Zhou  1 , Hongyan Niu  1 , Min Yang  1
Affiliations

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients

Wenhui Wu et al. Ren Fail. 2024 Dec.

Abstract

Objective: To explore independent influencing factors for clinical efficacy of roxadustat in hemodialysis patients.

Methods: Hemodialysis patients treated with roxadustat were enrolled. The plasma trough concentrations of roxadustat were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). A multiple logistic regression model was established to determine the factors that affect clinical efficacy of roxadustat in patients undergoing hemodialysis.

Results: A total of 67 hemodialysis patients were enrolled in the study. The results showed that age, blood trough concentration of roxadustat, and baseline hemoglobin (Hb) level were independent factors of clinical efficacy of roxadustat (OR = 1.06, p = .025 for age; OR = 1.001, p = .037 for plasma concentration; and OR = 0.941, p = .003 for baseline Hb), with an AUC score of 0.859.

Conclusions: Age, blood trough concentration of roxadustat, and baseline Hb level were independent influencing factors of the response to roxadustat in hemodialysis patients.

Keywords: Roxadustat; blood trough concentration of roxadustat; clinical efficacy; renal anemia.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
The flowchart of study design.
Figure 2.
Figure 2.
Receiver operating characteristic curve analysis evaluating the predictive ability of variables. The AUC of the model for predictive power of clinical efficacy was 0.859 (95%CI: 0.763–0.955); the AUC of blood trough concentration for predictive power of clinical efficacy was 0.647 (95%CI: 0.508–0.787); the AUC of age for predictive power of clinical efficacy was 0.64 (95%CI: 0.504–0.776); the AUC of baseline Hb for predictive power of clinical efficacy was 0.76 (95%CI: 0.642–0.897). AUC: area under the curve; Hb: hemoglobin.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Wingard RL, Chan KE, Lazarus JM, et al. . The "right" of passage: surviving the first year of dialysis. Clin J Am Soc Nephrol. 2009;4(Suppl. 1):1–7. doi: 10.2215/CJN.04360709. - DOI - PubMed
    1. Liu J, Yang F, Waheed Y, et al. . The role of roxadustat in chronic kidney disease patients complicated with anemia. Korean J Intern Med. 2023;38(2):147–156. doi: 10.3904/kjim.2022.318. - DOI - PMC - PubMed
    1. Johnson DW, Pollock CA, Macdougall IC.. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology. 2007;12(4):321–330. doi: 10.1111/j.1440-1797.2007.00810.x. - DOI - PubMed
    1. Macdougall IC, White C, Anker SD, et al. . Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447–458. doi: 10.1056/NEJMoa1810742. - DOI - PubMed
    1. Sakaguchi Y, Hamano T, Wada A, et al. . Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30(6):1037–1048. doi: 10.1681/ASN.2018101007. - DOI - PMC - PubMed